# Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

> **NCT02901587** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 119 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Lu AF35700 (10 mg/day)
- **DRUG:** Lu AF35700 (30 mg/day)
- **DRUG:** Quetiapine (Seroquel XR® 800 mg/day)

## Key facts

- **NCT ID:** NCT02901587
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-04-18
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02901587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02901587, "Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02901587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*